Company Analysis Bicycle Therapeutics plc
1. Summary
Advantages
- Price (11.1 $) is less than fair price (21.59 $)
Disadvantages
- Dividends (0%) are below the sector average (0.5351%).
- The stock's return over the last year (-57.27%) is lower than the sector average (-27.93%).
- Current debt level 5.98% has increased over 5 years from 1.72%.
- The company's current efficiency (ROE=-48.71%) is lower than the sector average (ROE=9.78%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Bicycle Therapeutics plc | Healthcare | Index | |
|---|---|---|---|
| 7 days | -9.5% | -21.5% | -5.3% |
| 90 days | -45.5% | -28.6% | -3.5% |
| 1 year | -57.3% | -27.9% | 15.9% |
BCYC vs Sector: Bicycle Therapeutics plc has significantly underperformed the "Healthcare" sector by -29.34% over the past year.
BCYC vs Market: Bicycle Therapeutics plc has significantly underperformed the market by -73.19% over the past year.
Stable price: BCYC is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: BCYC with weekly volatility of -1.1% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (11.1 $) is lower than the fair price (21.59 $).
Price significantly below the fair price: The current price (11.1 $) is 94.5% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (1840) is higher than that of the sector as a whole (57.27).
P/E vs Market: The company's P/E (1840) is higher than that of the market as a whole (49.14).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (1.79) is lower than that of the sector as a whole (4.64).
P/BV vs Market: The company's P/BV (1.79) is lower than that of the market as a whole (3.44).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (24.55) is lower than that of the sector as a whole (33.44).
P/S vs Market: The company's P/S indicator (24.55) is higher than that of the market as a whole (10.29).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-1.07) is higher than that of the sector as a whole (-17.68).
EV/Ebitda vs Market: The company's EV/Ebitda (-1.07) is lower than that of the market as a whole (25.46).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 50.85% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (50.85%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (106.41%).
5.4. ROE
ROE vs Sector: The company's ROE (-48.71%) is lower than that of the sector as a whole (9.78%).
ROE vs Market: The company's ROE (-48.71%) is lower than that of the market as a whole (8.96%).
5.5. ROA
ROA vs Sector: The company's ROA (-30.35%) is lower than that of the sector as a whole (0.33%).
ROA vs Market: The company's ROA (-30.35%) is lower than that of the market as a whole (6.33%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (-27.25%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (-27.25%) is lower than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5351%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 16.12.2024 | BAKER BROS. ADVISORS LP Director |
Purchase | 15.34 | 7 670 000 | 500 000 |
| 13.12.2024 | BAKER BROS. ADVISORS LP Director |
Purchase | 13.76 | 13 559 100 | 985 397 |
| 03.10.2024 | Lee Kevin Officer |
Purchase | 22.56 | 72 463 | 3 212 |
| 11.04.2024 | Hannay Michael Charles Ferguso CHIEF PROD & SUPPLY CHAIN OFF |
Sale | 22.49 | 5 780 | 257 |
| 03.01.2024 | Crockett Nigel Chief Business Officer |
Sale | 17.5 | 46 253 | 2 643 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
